Focus:
News
-
22 July 2019
Gilead gets licences to three antiviral programmes from Novartis
Gilead Sciences has secured an antiviral deal with Novartis to gain exclusive global rights to preclinical programmes involving candidates for the treatment of various viral infections.
-
22 July 2019
Janssen files submission for subcutaneous Darzalex in Europe
Janssen Pharmaceutical has submitted an application to the European Medicines Agency (EMA) seeking approval for subcutaneous formulation of Darzalex (daratumumab) to treat multiple myeloma.
-
19 July 2019
Boehringer forms alliance with Bridge Biotherapeutics for IPF drug
Boehringer Ingelheim has entered a collaboration and licence agreement to develop South Korea-based Bridge Biotherapeutics’ drug candidate for fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF).
-
19 July 2019
UK’s NICE backs Novartis breast cancer drug Kisqali
The UK’s National Institute for Health and Care Excellence (NICE) has approved Novartis’ drug Kisqali (ribociclib) in combination with fulvestrant for the treatment of certain patients with advanced breast cancer.
-
19 July 2019
Mallinckrodt partners with Silence Therapeutics for RNAi drugs
Mallinckrodt has partnered with Silence Therapeutics for the development and commercialisation of RNA interference (RNAi) drugs to treat patients with complement-mediated diseases.
-
18 July 2019
Researchers develop ‘Trojan horse’ chemo drug delivery system
Northwestern University researchers have developed a drug delivery system that can disguise chemotherapy drugs as fat, meaning that tumours readily consume them, the drugs are then activated to suppress tumour...
-
18 July 2019
Merck’s Recarbrio gets FDA approval for treatment of infections
The US Food and Drug Administration (FDA) has approved Merck’s Recarbrio injection for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (cIAI).
-
18 July 2019
Astellas licences Frequency Therapeutics’ hearing loss drug
Astellas Pharma has signed an exclusive licensing agreement to develop and commercialise Frequency Therapeutics’ drug candidate FX-322 for sensorineural hearing loss.
-
18 July 2019
AUM Biosciences to develop Inflection’s cancer therapy
Biotechnology firm AUM Biosciences has entered a global licence agreement for Inflection Biosciences’ series of PIM/PI3K/mTOR inhibitor molecules.
-
17 July 2019
Gotham and Mercachem generate epitranscriptomic target library
New York-based RNA-focused drug discovery company Gotham Therapeutics and German contract research organization (CRO) Mercachem have announced they have created a high-quality compound library focused on epitranscriptomic drug discovery.